<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mohammad Saiful Ardhi</style></author><author><style face="normal" font="default" size="100%">Muhammad Hamdan</style></author><author><style face="normal" font="default" size="100%">Achmad Chusnu Romdhoni</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of Thiamine on Serum Glutamate in Ischemic Stroke Animal Model</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Animal model</style></keyword><keyword><style  face="normal" font="default" size="100%">Glutamate</style></keyword><keyword><style  face="normal" font="default" size="100%">Ischemic</style></keyword><keyword><style  face="normal" font="default" size="100%">Stroke.</style></keyword><keyword><style  face="normal" font="default" size="100%">Thiamine</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">April 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">390-392</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background&lt;/strong&gt;: Thiamin or vitamin b1 is a therapy that has been widely used in neurology cases such as alcohol-induced encephalopathy and neuropathy. Thiamin has the ability to penetrate the blood brain barrier so that it is expected to be used as an additional therapy in stroke cases. Stroke is currently an emergency neurology case that causes high mortality and disability. Among the causes is because damage to large areas of the brain will cause the release of neurotransmitters such as glutamate which has excitotoxicity effects to the brain when excessive. &lt;strong&gt;Method: &lt;/strong&gt;This study used animal models of carotid artery occlusion stroke. Divided into 4 groups: control, thiamin dose of 100mg/kg, Thiamin 200mg/kg, and 400mg/kg. Serum glutamate was collected on day 7 post-action. Then evaluated by ELISA method. &lt;strong&gt;Results:&lt;/strong&gt; There was a significant difference in the form of a decrease in the average serum glutamate level between the control and the sample that received a dose of thiamine 200mg/kg and 400mg/kg. &lt;strong&gt;Conclusion: &lt;/strong&gt;High-dose thiamine may be considered as an additional therapy in cases of carotid artery occlusion model stroke.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">390</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p&gt;&lt;strong&gt;Mohammad Saiful Ardhi&lt;sup&gt;1,2&lt;/sup&gt;, Muhammad Hamdan&lt;sup&gt;2,*&lt;/sup&gt;, Achmad Chusnu Romdhoni&lt;sup&gt;3&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;1&lt;/sup&gt;Doctoral Program of Medical Science, Faculty of Medicine, Universitas Airlangga, Surabaya 60132, INDONESIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Neurology, Faculty of Medicine, Universitas Airlangga - Dr. Soetomo General Academic Hospital, Surabaya, 60132, INDONESIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;3&lt;/sup&gt;Department of Otorhinolaryngology Head and Neck Surgery, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Academic Hospital, Surabaya, 60132, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Muhammad Hamdan</style></author><author><style face="normal" font="default" size="100%">Priya Nugraha</style></author><author><style face="normal" font="default" size="100%">Pramitha Nayana Librata</style></author><author><style face="normal" font="default" size="100%">Cindy Cecilia</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Nonmotoric Symptoms Scale (NMSS) Validity and Reliability Test in Patients with Parkinson's Disease in Dr. Soetomo General Hospital, Surabaya, Indonesia: A Questioner Validation Study</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Nonmotoric Symptoms Scale</style></keyword><keyword><style  face="normal" font="default" size="100%">Parkinson’s disease</style></keyword><keyword><style  face="normal" font="default" size="100%">Validation</style></keyword><keyword><style  face="normal" font="default" size="100%">Validity</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">June 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">316-320</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background: &lt;/strong&gt;Nonmotor symptoms are common but less reported in Parkinson's disease. it’s the cause of decreased quality of life and disability in many patients with Parkinson's disease compared to the motor symptom. Our study aimed to translate the original English-language version of the nonmotor symptom scale (NMSS) into the Indonesian version of the NMSS. And also to evaluate its validity and reliability for use in Indonesian-speaking Parkinson's disease patients. This for better and valid usage of NMSS scale in the Indonesian patient and health care provider &lt;strong&gt;Material and Method: &lt;/strong&gt;This was descriptive-analytic study. Cross-cultural adaptation of NMSS and psychometric analysis of the Indonesian version of NMSS was carried out from 2 Teaching Hospital centers in Surabaya, East Java. Several other scales were also examined, including MMSE, ESS, BDI, and Scopa-Aut. A reliability test was performed using Alpha Cronbach.&lt;strong&gt; Results:&lt;/strong&gt; A total of 35 patients were included in this study. the average age was 64.03±12.92 with the female sex 42.9% (n=15) and the male 57.1% (n=20), and Hoehn and Yahr stage II 57.1% (n=20). The total average NMSS is 11.64. The validity of contents and constructs of the NMSS on each domain has been proven valid. Internal reliability of internal consistency in these tools with an alpha Cronbach value of 0.836. Each domain correlates with several other scores including MMSE, BDI, ESS, and Scopa-aut. &lt;strong&gt;Conclusion:&lt;/strong&gt; The Indonesian version of NMSS has good validity and reliability in assessing nonmotor symptoms in Parkinson's disease patients in Indonesia.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><work-type><style face="normal" font="default" size="100%">Original Article </style></work-type><section><style face="normal" font="default" size="100%">316</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Muhammad Hamdan*, Priya Nugraha, Pramitha Nayana Librata, Cindy Cecilia&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Neurology, Faculty of Medicine, Airlangga University – Dr. Soetomo General Academic Teaching Hospital, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Olivia Mahardani Adam</style></author><author><style face="normal" font="default" size="100%">Jusak Nugraha</style></author><author><style face="normal" font="default" size="100%">Muhammad Hamdan</style></author><author><style face="normal" font="default" size="100%">Agus Turchan</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Mechanism of the Bioactive Sargassum cristaefolium in Inhibiting Inflammatory Mediators in a Nitroglycerin-Induced Migraine Model in Rats</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Inflammatory mediator</style></keyword><keyword><style  face="normal" font="default" size="100%">Migraine</style></keyword><keyword><style  face="normal" font="default" size="100%">Nitroglycerin</style></keyword><keyword><style  face="normal" font="default" size="100%">Sargassum cristaefolium</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">April 2022</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">14</style></volume><pages><style face="normal" font="default" size="100%">388-396</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background&lt;/strong&gt;: Migraine headaches are a form of sterile neurogenic inflammation. The sterile inflammatory process of the trigeminal nerve releases the vasoactive neuropeptide CGRP which stimulates the release of inflammatory mediators. In the incidence of migraine there is an increase in TNF-α and IL-10. &lt;em&gt;Sargassum cristaefolium&lt;/em&gt; ethanol extract contains flavonoids, alkaloids, triterpenoids, steroids, and tannins, which has analgesic and anti-inflammatory function. &lt;strong&gt;Method: &lt;/strong&gt;&lt;em&gt;Sargassum cristaefolium &lt;/em&gt;was extracted using maceration method with 70% ethanol as solvent. Animal models were divided into 5 groups and given NTG induction 5 times with 1 day intervals, treated for 3 weeks. All data were analyzed using IBM SPSS version 26.0. &lt;strong&gt;Results: &lt;/strong&gt;&lt;em&gt;Sargassum cristaefolium&lt;/em&gt; ethanol extract - CGRP levels β: -0.26, p: 0.17; &lt;em&gt;Sargassum cristaefolium&lt;/em&gt; ethanol extract - CGRP expression β: -0.04, p: 0.85; &lt;em&gt;Sargassum cristaefolium&lt;/em&gt; ethanol extract - TNF-α levels β: -0.63, p: 0.01; &lt;em&gt;Sargassum cristaefolium &lt;/em&gt;ethanol extract - TNF-α expression β: -0.40, p: 0.04; &lt;em&gt;Sargassum cristaefolium&lt;/em&gt; ethanol extract - IL-10 levels β: 0.77, p: 0.00; &lt;em&gt;Sargassum cristaefolium &lt;/em&gt;ethanol extract - IL-10 expression β: 0.45, p: 0.01.&lt;strong&gt; Conclusions&lt;/strong&gt;: A significant path between the administration of &lt;em&gt;Sargassum cristaefolium &lt;/em&gt;ethanol extract and a decrease in TNF-α and an increase in IL-10. But the effect of giving &lt;em&gt;Sargassum cristaefolium &lt;/em&gt;ethanol extract on CGRP levels did not have a significant relationship.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue><work-type><style face="normal" font="default" size="100%">Research Article </style></work-type><section><style face="normal" font="default" size="100%">388</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Olivia Mahardani Adam&lt;sup&gt;1,2&lt;/sup&gt;, Jusak Nugraha&lt;sup&gt;3,*&lt;/sup&gt;, Muhammad Hamdan&lt;sup&gt;4&lt;/sup&gt;, Agus Turchan&lt;sup&gt;5&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Doctoral Program, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Neurology, Faculty of Medicine, Universitas Hang Tuah, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Department of Clinical Pathology, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;Department of Neurology, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;5&lt;/sup&gt;Department of Neurosurgery, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record></records></xml>